about
Coronary microvascular endothelial cell growth regulates expression of the gene encoding p22-phoxMolecular characterization and localization of the NAD(P)H oxidase components gp91-phox and p22-phox in endothelial cellsNitric oxide synthase and NAD(P)H oxidase modulate coronary endothelial cell growthRole of gender, smoking profile, hypertension, and diabetes on saphenous vein and internal mammary artery endothelial relaxation in patients with coronary artery bypass grafting.Free radicals, diabetes and endothelial dysfunction.Risk factors for ischaemic stroke.Epidemiology, pathophysiology, and treatment of hypertension in ischaemic stroke patients.Differential mechanisms of angiotensin II and PDGF-BB on migration and proliferation of coronary artery smooth muscle cells.Hyperglycaemia promotes human brain microvascular endothelial cell apoptosis via induction of protein kinase C-ßI and prooxidant enzyme NADPH oxidase.Expression of the human gene encoding urokinase plasminogen activator receptor is activated by disruption of the cytoskeleton.Effects of angiotensin II on nitric oxide generation in proliferating and quiescent rat coronary microvascular endothelial cells.Small GTPase RhoA and its effector rho kinase mediate oxygen glucose deprivation-evoked in vitro cerebral barrier dysfunction.Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-β.Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells.Vitamins reverse endothelial dysfunction through regulation of eNOS and NAD(P)H oxidase activities.Investigation of the C242T polymorphism of NAD(P)H oxidase p22 phox gene and ischaemic heart disease using family-based association methods.Impaired activities of antioxidant enzymes elicit endothelial dysfunction in spontaneous hypertensive rats despite enhanced vascular nitric oxide generation.Antioxidant vitamins C and E ameliorate hyperglycaemia-induced oxidative stress in coronary endothelial cells.Antioxidants attenuate hyperglycaemia-mediated brain endothelial cell dysfunction and blood-brain barrier hyperpermeability.Blockade of angiotensin II provides additional benefits in hypertension- and ageing-related cardiac and vascular dysfunctions beyond its blood pressure-lowering effects.NADPH oxidase mediates TNF-α-evoked in vitro brain barrier dysfunction: roles of apoptosis and time.Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury through modulations of endothelial cell oxidative stress and tight junctions.Expression of functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells.Increases in intracellular calcium perturb blood-brain barrier via protein kinase C-alpha and apoptosis.Inhibition of TNF-α protects in vitro brain barrier from ischaemic damage.Suppression of PKC-α attenuates TNF-α-evoked cerebral barrier breakdown via regulations of MMP-2 and plasminogen-plasmin system.Attenuation of urokinase activity during experimental ischaemia protects the cerebral barrier from damage through regulation of matrix metalloproteinase-2 and NAD(P)H oxidase.Selective dysregulation of nitric oxide synthase type 3 in cardiac myocytes but not coronary microvascular endothelial cells of spontaneously hypertensive ratN-acetylcysteine does not improve the endothelial and smooth muscle function in the human saphenous vein
P50
Q28570713-6AB19DE0-AF3F-4B6B-9C35-7935E9D1EDACQ28570949-1CB8081C-0454-4E03-A89F-612A5FCE163EQ28577775-92DC27C7-B27B-4B63-8DAD-862224352C42Q34185770-8167E985-E02A-4A7E-8616-F6BB60FA510FQ34722600-87C743F6-E788-4132-9B8A-5EC3273F7840Q37244553-B588007D-73A7-4632-9CCB-505A4C663682Q38017466-90E62439-0FA7-4036-A9A6-C7787E86842AQ39969153-CAD299E1-8140-498E-A47D-47F27FE781DBQ40546792-9FEB862B-361A-44E8-B0FF-AE03DC78B300Q41268539-1EAC55D8-335A-4DE0-BD82-054506B15DFAQ42452872-A7AB7F4F-F91C-4BA9-8084-DE4C6E8E7C96Q42961948-1EF23299-2162-4714-A88D-D7B8C3B357EFQ43407851-5BF77EB0-370F-4C9A-838E-FE03432552ADQ44100847-4FE06B91-F691-40C0-8817-353ACC295258Q44353766-73285D8E-B187-4C20-A3F6-2583E7C635A5Q44523377-690ECC7C-065F-482D-8B3D-53676CFD04D5Q44543604-BE2E6B45-ECE0-4BC6-AED6-78D24B3F8598Q45102899-01266069-4FB8-4B31-8423-12412342E745Q46112655-FF715BFE-D2FB-4FBC-9FFE-3A31435D106AQ46790680-B8F6CF59-FAA4-4A08-AE6A-A4C0FE53045BQ46882752-DEC1B4C4-BDD6-45F8-B4BD-224A61AFB514Q46931764-4F8E8D22-62FF-4402-9F0D-FCF850A8FB4CQ47767150-17749EF0-F303-41BB-BEF5-E4E65A2517A3Q50207726-4CD1365F-0052-4EE5-A0D7-1F2CD1FBC9F0Q50915151-92D38363-57B5-4D00-B16A-4FAA9FE4BC30Q52139101-F31D94D5-EF56-4B53-A15B-EC741800673CQ52648658-9414D9C6-47DA-4CA5-8309-6FF271744A66Q61843041-615CD16D-E89C-4FDA-A461-A9B66FD9948BQ80535815-D3C60DBA-5C98-454B-88BD-C17DED843FF6
P50
description
researcher ORCID ID = 0000-0001-6922-0237
@en
wetenschapper
@nl
name
Ulvi Bayraktutan
@ast
Ulvi Bayraktutan
@en
Ulvi Bayraktutan
@es
Ulvi Bayraktutan
@nl
type
label
Ulvi Bayraktutan
@ast
Ulvi Bayraktutan
@en
Ulvi Bayraktutan
@es
Ulvi Bayraktutan
@nl
prefLabel
Ulvi Bayraktutan
@ast
Ulvi Bayraktutan
@en
Ulvi Bayraktutan
@es
Ulvi Bayraktutan
@nl
P1153
6603092056
P31
P496
0000-0001-6922-0237